Necroptosis has been reported to enhance anti-tumor immunity in colon cancer and melanoma [41, 42] and RIPK3 expression status is proposed to influence the clinical outcome of TLR3-based cancer immunotherapy [45]. Here, RIPK3 is linked to melanoma.